Theravance Biopharma Agrees to $17.00/Share Cash Acquisition by Zymeworks, Plus CVR
TBPH sits 67% above its 52-week low of $10.578 on elevated volume (3.0× avg).
Summary
Theravance Biopharma has entered a definitive agreement to be acquired by Zymeworks for $17.00 per share in cash, plus a Contingent Value Right. This acquisition provides a clear resolution to the strategic review for a potential company sale that Theravance Biopharma announced on April 28th. The cash offer is slightly below the current trading price, suggesting the market is assigning value to the CVR or anticipating a potential higher bid. This event fundamentally changes the investment thesis for TBPH shareholders.
At the time of this announcement, TBPH was trading at $17.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $908.9M. The 52-week trading range was $10.58 to $21.03. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.